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A B S T R A C T
Background: To address rising drug-related harms (including significant transmission of HIV) among people who
inject drugs (PWID) in Glasgow, officials have proposed the introduction of the UK's first drug consumption room
(DCR) in Glasgow city centre. Using a nationally representative sample, this study aimed to determine will-
ingness to use a DCR among PWID nationally, in Glasgow city centre (the proposed DCR location), other Scottish
city centres (excluding Glasgow) and the rest of Scotland (excluding city centres).
Methods: Bio-behavioural survey, of 1469 current PWID (injected in last 6 months) across Scotland during 2017-
18. Willingness to use DCRs was examined by drug-related risk behaviours and harms overall in Scotland, and
then stratified by Glasgow city centre (n = 219), other Scottish city centres (n = 226) and the rest of Scotland
(n = 1024).
Results: The majority of PWID overall in Scotland (75%) were willing to use a DCR; willingness was higher
among those recruited in Glasgow city centre (83%) and other Scottish city centres (83%), compared to the rest
of Scotland (72%) (p< 0.001). Willingness was greater among PWID who reported (compared to those who did
not report) injecting heroin (76%, p = 0.002), cocaine injecting (79%, p = 0.014), homelessness (86%,
p < 0.001), public injecting (87%, p < 0.001) and an overdose (80%, p = 0.026). Willingness was found to be
associated with a cumulative multiple risk variable: increased from 66% among those with a score of zero to 85%
with a score of at least three (p < 0.001).
Conclusions: The vast majority of PWID at greatest risk of drug-related harm in Glasgow and elsewhere in
Scotland would be willing to use a DCR, supporting proposals for the introduction of DCRs nationally.
Introduction
Internationally, there has been an increase in drug-related deaths in
recent years, including in Scotland, where figures have reached record
levels and are among the highest in Europe (National Records of
Scotland, 2019). In addition, there have been recent major outbreaks of
infectious disease among people who inject drugs (PWID) in Scotland
and the Scottish city of Glasgow; these have included anthrax, the
largest outbreak of wound botulism among PWID ever recorded in
Europe (Trayner et al., 2018) and the largest outbreak of HIV among
PWID observed in the UK for over 30 years, which has resulted in a
rapid rise in HIV prevalence from 1% to 11% among PWID in Glasgow
city centre (McAuley et al., 2019).
To address the rise in drug-related health burden among PWID in
Glasgow, a needs assessment focusing on public drug use was published
in 2016, which proposed the establishment of the UK's first drug con-
sumption room (DCR) and co-located heroin assisted treatment (HAT)
service located in Glasgow city centre (Tweed, Rodgers, Priyadarshi, &
https://doi.org/10.1016/j.drugpo.2020.102731
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Crighton, 2018). The HAT service was established in November 2019,
embedded in a service providing care for those experiencing home-
lessness. However, despite attracting widespread support from Scottish
Government, local authorities, health officials, some sections of the
media (Atkinson, McAuley, Trayner, & Sumnall, 2019), and police, the
proposals for a DCR have been repeatedly rejected by the UK Govern-
ment, on the basis of a lack of an appropriate legal framework for the
facility to operate under the Misuse of Drugs Act 1971. The UK Gov-
ernment reiterated its objection to DCRs at the UK Drug-Related Death's
summit, held in Glasgow on the 27th of February 2020
(BBC news, 2020).
Drug consumption rooms are healthcare settings, which provide a
safe and clean environment for the consumption of drugs under the
supervision of medically trained staff and alongside provision of clean
injecting equipment. There are over 100 DCRs operating inter-
nationally, which are typically low threshold interventions that aim to
attract PWID at the highest risk of drug-related and social harm
(Pardo, Caulkins, & Kilmer, 2018). There is a large body of literature
which supports the introduction of DCRs, with a particularly strong
case for areas of the world, such as Glasgow, which are undergoing
significant public health crises among PWID. Published studies suggest
that DCRs are successful in attracting the most marginalised PWID,
reduce overdose morbidity and mortality, promote safer injection
conditions and enhance access to health and social services
(Caulkins, Pardo, & Kilmer, 2019; Pardo et al., 2018).
Reluctance to implement DCRs in Scotland may be, in part, hin-
dered by lack of evidence on the willingness of PWID to use the service.
Internationally, a number of studies have assessed the acceptability of
DCRs among PWID at a local or regional level (Bouvier, Elston,
Hadland, Green, & Marshall, 2017; Butler, Chapman, & Terry, 2018;
Fry, Fox, & Rumbold, 1999; Green, Hankins, Palmer, Boivin, & Platt,
2004; O'Rourke et al., 2019). Willingness to use DCRs has been asso-
ciated with drug-related risk factors such as public injecting, home-
lessness, cocaine injecting, history of overdose and frequent drug use
(Bouvier et al., 2017; Green et al., 2004; O'Rourke et al., 2019). We here
assess willingness to use a DCR among a large national sample of PWID,
overall in Scotland and also stratified by Glasgow city centre (location
of an ongoing outbreak of HIV and planned location of the DCR),
Scottish city centres (excluding Glasgow) and the rest of Scotland. This
study therefore aimed to investigate willingness to use a DCR among
PWID Scotland, in light of the proposals to establish the UK's first DCR.
Methods
Data source
This research utilised a national anonymous, bio-behavioural, cross-
sectional survey known as the Needle Exchange Surveillance Initiative
(NESI). NESI aims to measure the prevalence of blood-borne viruses
(BBV) and injecting risk behaviours among PWID across mainland
Scotland. Trained independent interviewers recruited PWID from over
100 services providing injecting equipment and other harm reduction
interventions (approximately half of the total number of services across
Scotland). Inclusion of PWID who have not injected recently (in past six
months) is capped at 30% to ensure that the majority of the sample
represents recent PWID (defined as those who injected in the past six
months). After providing informed consent, participants complete an
interviewer-led questionnaire and then provide a dried blood spot
(DBS) sample, which is tested anonymously for BBV markers as de-
scribed elsewhere (Health Protection Scotland, 2019). A question re-
lating to willingness to use a DCR was included in the survey conducted
between July 2017 and October 2018. Thus, this analysis was confined
to recent PWID (injected in last six months) surveyed during 2017-18.
Measures
The primary outcome of interest was willingness to use a DCR. This
was ascertained by providing a short description of a DCR: “A drug
consumption room is a place where you can bring your drugs to inject
or smoke in a safe environment. You can also get clean works, help with
injecting technique and other advice”, followed by the question “would
you use a drug consumption room if it were made available in your
area?” (answered yes/no). Willingness was explored according to de-
mographic, injecting risk behaviour and harm variables. Exposures of
interest (in the last six months unless stated otherwise) included: age,
sex, homelessness (yes/no), injected heroin (yes/no), injected powder
cocaine (yes/no), injected in a public place (yes/no), HIV infection,
current HCV infection, overdosed in the last year (yes/no) and skin and
soft tissue infection in the last year (SSTI) (yes/no). HIV and HCV in-
fection were confirmed by laboratory DBS tests. Samples which tested
both HCV antibody and PCR positive represented those with current
HCV infection. A multiple risk variable was calculated as the sum of the
following individual risk factors: cocaine injecting, injecting in a public
place, sharing needles/syringes, high injecting frequency (≥4 times per
day), and re-using needles/syringes. A participant received a score of
one for each risk factor that was present, with a maximum score of five
(those with a score of 3, 4 or 5 were grouped given too few observa-
tions).
Analysis
Proportions of those willing to use a DCR were compared across
demographic, injecting risk behaviour and harm variables using chi-
squared tests of association across the total Scottish sample. Given
proposals to establish a DCR in Glasgow city centre, we further strati-
fied the analysis by; Glasgow city centre (n = 219), other Scottish city
centres (excluding Glasgow) (hereafter “Scottish city centres”)
(n = 226) and rest of Scotland (excluding city centres) (hereafter “rest
of Scotland”) (n = 1024). We used a significance level of p < 0.05.
Any co-variates which were associated with willingness to use a
DCR (in overall or stratified analysis) at a univariate level were in-
cluded in a logistic regression model. We included: recruitment region,
homelessness, injecting heroin, reporting an overdose in the last year
and our multiple risk variable. Variables which were already included
in the multiple risk variable (cocaine injecting and public injecting)
were not included in the model. The results of the model are described
in the results; the full model can be viewed in the Appendix. Analysis
was undertaken using Stata 13.
Results
Our sample included 1469 PWID, 15% (219/1469) were recruited
in Glasgow city centre, 15% (226/1469) in Scottish city centres and
70% (1024/1469) in the rest of Scotland. The majority were male
(75%, 1099/1465) and aged 35-44 years old (52%, 769/1468). Just
over a quarter had experienced recent homelessness (27%, 402/1467).
The vast majority (92%, 1347/1465) had injected heroin in the last six
months and 31% (452/1464) had injected powder cocaine. The pre-
valence of HIV and current HCV among participants was 3% (42/1367)
and 33% (403/1247), respectively. In the last year, 18% (265/1437)
had experienced an overdose and 28% (402/1456) an SSTI. A higher
proportion of PWID recruited in Glasgow city centre reported recent
homelessness (57%, 124/218), cocaine injecting (74%, 161/219) and
public injecting (47%, 102/219) when compared to other regions
(Table 1).
We found overall willingness to use a DCR in Scotland was 75%;
willingness was higher among those recruited in Glasgow city centre
(83%) and other Scottish city centres (83%), compared to the rest of
Scotland (72%) (p < 0.001). We found a higher willingness among
PWID who reported injecting heroin (76%) compared to those who did
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not (63%) (p = 0.002), with a similar result across all stratified regions.
Similarly, those who reported recent homelessness in Scotland (86%),
reported a higher willingness compared to those who did not (71%,
p < 0.001), which was found across all regions. Other risk factors
where PWID reported a higher willingness were those who reported
public injecting (87% vs. 72%, p < 0.001), cocaine injecting (79% vs.
73%, p = 0.014) and reporting an overdose in the last year (80% vs.
74%, p = 0.026), with similar rates found across all regions (Table 1).
An increasing significant positive trend was found across all regions
in relation to an increasing score in our cumulative risk variable.
Among the total sample, PWID with the lowest score (0) had the lowest
willingness (66%), compared to 85% (p < 0.001) with the highest
(score of three, four or five) (Table 1).
In our multi-variate analysis, PWID recruited in Scottish city centres
(aOR=1.62, 95% CI 1.10 to 2.39, p = 0.014) had a significantly higher
odds of reporting willingness when compared to individuals recruited
from the rest of Scotland. Those who reported homelessness (relative to
those who did not) (aOR=2.06, 95% CI 1.47 to 2.89, p < 0.001) and
injecting heroin (compared to those who did not) (aOR=2.07, 95% CI
1.35 to 3.18, p = 0.001) were associated with an increased odds of
reporting willingness to use a DCR. When compared to a baseline score
of 0, all scores in our cumulative risk variable were associated with
increased odds of reporting willingness. The highest odds were found
(aOR=2.29, 95% CI 1.37 to 3.83, p = 0.001) among PWID who had a
score of 3, 4 or 5, when compared to those who had a score of 0
(Appendix 1).
Discussion
In the context of proposals to establish the UK's first DCR in
Glasgow, we found that the vast majority (75%) of PWID in Scotland
expressed willingness to use a DCR. The high level of willingness to use
a DCR among PWID in Scotland is consistent with other studies which
have been conducted in cities elsewhere in the UK (London and Leeds)
(84-89%) (Butler et al., 2018; Hunt, Lloyd, Kimber, & Tompkins, 2007)
and in North America (76-87%) (Bouvier et al., 2017; Green et al.,
2004). Furthermore, studies in cities which have successfully in-
troduced DCRs, such as Vancouver (92%) (Kerr, Wood, Small, Palepu, &
Tyndall, 2003) and Melbourne (77%) (Fry et al., 1999) showed similar
acceptability rates prior to their introduction.
Previous research has shown that the voices of PWID have been left
out of the debate for a DCR in Glasgow (Atkinson et al., 2019), until
now. We found a particularly high willingness among those recruited in
Glasgow city centre (83%), which may reflect increased awareness of
DCRs in Glasgow, given the local proposals, where individuals may
have had more time to consider the benefits/drawbacks. However,
PWID recruited in other Scottish city centres (83%) also reported high
willingness which is an important result, as DCRs are normally estab-
lished in cities, close to open drug markets that are experiencing issues
with public drug use. These results are also encouraging given the
planned location of the DCR in Glasgow (Tweed et al., 2018), and for
any other cities in Scotland which may consider introducing DCRs in
the future.
Outside of city centres, willingness to use a DCR in the rest of
Scotland was also high (72%), one reason for this may be related to
contemporaneous media interest and reporting on DCRs in the UK
(Atkinson et al., 2019). If a change in legal framework allowed for the
introduction of DCRs, services (such as mobile DCRs) would need to be
considered to meet the demand outside of city centres. Assessing self-
reported willingness to use DCRs has been shown to be a good predictor
of subsequent attendance and use of DCRs; a study from Vancouver
reported that 72% of PWID who reported prior willingness later used
the service (DeBeck et al., 2012).
Key individual and environmental drivers of an increase in HIV
prevalence among PWID in Glasgow in recent years are a combination
of homelessness, cocaine injecting and public injecting (McAuley et al.,
2019; Trayner et al., 2020). We found a high willingness among PWID
reporting these risk factors (at levels of 79%-87% nationally, 84-87% in
Glasgow city centre, 75-92% in other Scottish city centres and 77-85%
in the rest of Scotland). Moreover, we found a positive association be-
tween cumulative risk and willingness, with willingness to use a DCR
increasing with a higher score in our cumulative risk variable (based on
self report of public injecting, cocaine injecting, sharing injecting
equipment, re-using injecting equipment and a high injecting fre-
quency). Our results indicate that if a DCR were piloted in Glasgow as
proposed, or elsewhere in Scotland, it would likely attract PWID with
the greatest risk of drug-related harm, consistent with previous research
(Bouvier et al., 2017; Butler et al., 2018; Fry et al., 1999; Green et al.,
2004; Wood et al., 2003).
Cities such as Vancouver were faced with similar health crises prior
to the establishment of DCRs. For example, before the establishment of
Insite (North Americas first DCR), Vancouver experienced a major
outbreak of HIV in the mid-1990s, and this was also driven by cocaine
injecting and homelessness (Tyndall et al., 2003). In addition to high
levels of public injecting, these were the main drivers for the estab-
lishment of the service. Evaluations of InSite showed that the number of
PWID injecting in public halved within 12 weeks of the facility opening
(Wood et al., 2004) and a mathematical modelling study predicted that
35 new HIV cases were prevented each year (Andresen & Boyd, 2010).
Furthermore, the fatal overdose rate decreased by 35% within 500m of
the DCR (Marshall, Milloy, Wood, Montaner, & Kerr, 2011). Given the
high willingness to use DCRs among high risk PWID in our survey, our
results suggest that the introduction of a DCR in Glasgow or elsewhere
could potentially yield similar results.
With regard to limitations, all data collected through NESI (apart
from BBV) status) is self-reported, which may be subject to response
and recall bias. However, the likelihood of response bias is minimised to
a certain extent by the use of independent researchers to collect data.
Additionally, a limitation is that these results are in the context of the
population having no experience of DCRs and thus may not have been
aware of DCRs prior to their interview. Our data relate to those who
attend services that provide injecting equipment, and thus may not fully
represent the PWID population in Scotland; however, other data from
elsewhere in Scotland (Tweed et al., 2018) highlighted that the ma-
jority of PWID are regular attendees of these services. Furthermore,
data was collected from 139 services providing injecting equipment
(approximately half of the total nationally) and our sample represents
an estimated 10-15% of the PWID population in Scotland.
Conclusion
The case for DCRs in Scotland, based on the extent of drug-related
harms alone, is compelling. We now provide further evidence to de-
monstrate that the vast majority of PWID, particularly those most at risk
of drug-related harm, in Glasgow and indeed elsewhere in Scotland
would be willing to use a DCR.
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